Tricol Biomedical Inc

What Tricol Biomedical Inc does

Tricol Biomedical Inc. is a fully integrated medical device company headquartered in Portland, Oregon that develops and commercializes hemostatic and wound-care products built around a proprietary chitosan platform. Founded in 2001 in partnership with the U.S. Army to address battlefield hemorrhage, the company now serves three end markets—trauma management (military and pre-hospital EMS), procedural care (hospitals, catheterization labs, dialysis centers, and dental offices), and consumer self-care—through sub-brands including HemCon®, OneStop™, ChitoGauze®, and Chito+™. Its technology has been deployed across more than 60 countries, with over one million dressings used since 2002 and no adverse events reported.

The company's technology platform rests on Chito+™, a proprietary chitosan derived from shrimp shells whose strong polycationic (positive) charge attracts negatively charged red blood cells to create rapid hemostasis independent of the body's normal clotting cascade. A complementary platform, m.doc®, uses micro-dispersed oxidized cellulose that works within the clotting cascade by activating FXII and platelets and forming a soft gel-like matrix. Product families include HemCon® (Bandage PRO, Patch PRO, ChitoDot, ChitoPulse, GuardaCare), OneStop™ (Vascular, Bandage, Vascular Pre-Slit), and ChitoGauze® (XR PRO, XR2 PRO, OTC, Trainers). Several lines carry Committee on Tactical Combat Casualty Care (CoTCCC) approval and incorporate x-ray-detectable threads for retained-dressing detection. The portfolio is protected by over 60 patents across the U.S., Europe, Israel, Korea, Canada, and Australia, with 30+ peer-reviewed clinical publications supporting efficacy claims.

Tricol generates revenue primarily through hardware sales of its hemostatic devices, with published unit pricing ranging from $21 for the consumer ChitoGauze OTC to $8,295 per case for HemCon Bandage PRO. The company operates a multi-channel go-to-market combining exclusive U.S. distribution through Medline Industries (acute care, North America), Salvin Dental Specialties (dental), and NorthStar Sales Alliance (alternate-site GPO channels), supplemented by Concordance Healthcare Solutions and trauma-product distributors (NAR, Chinook MED, Ever Ready First Aid), a network of international distributors across Europe, Asia, Africa, and the Middle East, and a direct-to-consumer e-commerce site. Secondary revenue streams include private-label/co-branding arrangements (notably with Safeguard Medical for ChitoGauze XR PRO) and non-dilutive NIH grant funding, with the European operation housed in a wholly-owned Czech subsidiary, HemCon Medical Technologies CZ s.r.o.

Name

Tricol Biomedical Inc

Legal name

Tricol Biomedical, Inc.

Website

https://tricolbiomedical.com

Company type

Private

Founded year

2001

Operating status

Operating

Headcount range

11–50 employees

Short description

Tricol Biomedical is a Portland-based medical device company that develops chitosan-based hemostatic dressings and wound-care products under the HemCon, OneStop, and ChitoGauze brands, serving military trauma, hospital procedural, dental, dialysis, and consumer self-care markets across more than 60 countries.

Ownership category

akta.pro rank

Product category

Hemostatic Wound Care Devices

NAICS

Surgical Appliance and Supplies Manufacturing (339113), Medical Equipment and Supplies Manufacturing (3391), Sanitary Paper Product Manufacturing (322291)

SIC

Surgical & Medical Instruments & Apparatus (3841), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Wholesale-Medical, Dental & Hospital Equipment & Supplies (5047)

akta.pro primary industry

First Aid & Wound Care (Bandages, Dressings, Antiseptics, Burn Care) (CRADAMAB)

akta.pro secondary industries

Wound Care & Ulcer Management (HLAKACAN), Wound, Ostomy & Continence Care (WOC) at Home (HSABACAE)

Keywords

• Hemostatic wound care
• Chitosan-based dressings
• Advanced wound management
• Trauma hemorrhage control
• Medical hemostatic devices

Headquarters

HQ city

Portland

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Operations, Technology or R&D, Marketing or Sales, Personnel, Supply Chain

Revenue model

1. Hemostatic Medical Device Sales: Tricol generates revenue through the sale of hemostatic medical devices including bandages, gauze, patches, and dressings. Products are sold as one-time purchases with pricing based on product type and quantity. Distribution occurs through direct sales, distribution partners, and e-commerce.
2. Licensing and Co-development: Revenue from licensing proprietary chitosan technology to partners for co-branded or private label products. Examples include agreement with Safeguard for co-branded ChitoGauze XR PRO and co-development with Tactical Medical Solutions.
3. NIH Grant Funding: Non-dilutive funding from National Institutes of Health for development of hemostatic devices, including $853,585 Phase IIB grant for prostate hemostatic device development.

Pricing tiers

Go-to-market motion2 records

Distribution channels7 records

Marketing channels5 records

Core offering

Tricol Biomedical develops, manufactures, and sells hemostatic wound care medical devices based on its proprietary Chito+™ chitosan technology platform, including bandages, gauze, patches, and dressings organized into Trauma Management, Procedural Care, Consumer Self-Care, and Dental product lines. The chitosan technology enables rapid bleeding control via a positive-charge mechanism that works independently of the body's natural clotting cascade, making it effective on anticoagulated and coagulopathic patients, while also providing an antibacterial barrier. Products are sold to hospitals, military/EMS, dental practices, dialysis centers, and consumers through exclusive distribution partners, GPOs, international distributors, and direct e-commerce.

Product overview

Tricol Biomedical is a fully integrated medical device company offering a portfolio of hemostatic and wound care products organized into three categories: Trauma Management, Procedural Care, and Consumer Care. The core technology platform is Chito+™ (proprietary chitosan) which works outside the clotting cascade by attracting negatively charged blood cells to create a clot, plus m.doc® (micro-dispersed oxidized cellulose) which works within the clotting cascade. Product families include HemCon® (Bandage PRO, Patch PRO, ChitoDot, ChitoPulse, GuardaCare), OneStop™ (Vascular, Bandage), and ChitoGauze® (XR PRO, XR2 PRO, OTC). The company also developed Absorbable Biocompatible Chitosan (ABC) for internal bleeding applications.

Differentiator

Problem solved

Functional benefit

Brands

• HemCon: Hemostatic chitosan-based product line including bandages, patches, and gauze dressings for trauma, procedural care, and consumer applications. The original battlefield-proven technology.
• OneStop
• Chito+
• ChitoGauze
• m.doc

Products and services

• HemCon® Bandage PRO A 4in x 4in chitosan-based wound dressing that controls bleeding caused by extreme trauma and provides an antibacterial barrier against MRSA, VRE, and Acinetobacter baumannii for trauma and emergency use.
• ChitoGauze® XR PRO CoTCCC-approved flexible hemostatic chitosan-coated gauze dressing with x-ray-detectable thread for external, temporary control of severely bleeding wounds in pre-hospital, military, and EMS settings.
• ChitoGauze® XR2 PRO CoTCCC-approved hemostatic chitosan-coated gauze with dual x-ray-detectable threads for external, temporary control of severely bleeding wounds in pre-hospital and military trauma applications.
• ChitoGauze® XR2 PRO Trainer Hemostatic chitosan-coated gauze dressing variant designed for training and instructional purposes only, mirroring the XR2 PRO design with 2 x-ray-detectable threads.
• OneStop™ Bandage Rx 2in x 2in chitosan wound dressing providing rapid bleeding control for patients on anticoagulation therapy plus an antibacterial barrier for hospital and outpatient procedural settings.
• HemCon Patch® PRO Hemostatic chitosan-based dressing in 1.5in x 1.5in and 2in x 2in sizes for external, temporary control of severely bleeding wounds in emergency settings, with antibacterial barrier against MRSA, VRE, and Acinetobacter baumannii.
• HemCon ChitoDot® 3/4in chitosan-based bandage for local management of bleeding wounds, providing rapid bleeding control for hemodialysis patients and those on anticoagulation therapy, with antibacterial barrier.
• HemCon ChitoPulse™ Radial compression device with an integrated hemostatic chitosan patch, available in 9in, 12in, and 15in sizes, for rapid control of bleeding following catheterization or puncture of radial artery blood vessels, including for hemodialysis and anticoagulated patients.
• OneStop™ Vascular Chitosan-based wound dressing providing rapid bleeding control for skin surface punctures during vascular procedures, including for anticoagulated patients, with antibacterial barrier; distributed to hospitals via Medline and GPO contracts.
• OneStop Vascular Pre-Slit 1.5in Pre-slit 1.5in chitosan-based wound dressing for skin surface puncture sites, vascular procedure sites, and percutaneous catheters, providing rapid bleeding control for anticoagulated patients.
• HemCon GuardaCare® PRO Hemostatic chitosan gauze dressing in 2in x 2in and 4in x 4in 8ply formats for external temporary control of severely bleeding wounds.
• HemCon GuardaCare® XR Surgical 4in x 4in z-fold 8ply hemostatic chitosan surgical dressing with x-ray-detectable thread for temporary control of severely bleeding surgical wounds and traumatic injuries.
• HemCon® Dental Dressing PRO Oral wound dressing utilizing chitosan for temporary protection of oral mucosal tissue wounds and pain relief following dental extractions; becomes adherent when in contact with the oral wound providing a protective layer.
• ChitoGauze® OTC Battlefield-proven hemostatic gauze dressing in 3in x 48in Z-fold format sold directly to consumers for temporary external use to stop bleeding in minor wounds.
• ChitoGauze® OTC XL Battlefield-proven hemostatic gauze dressing in 3in x 4yd Z-fold format sold directly to consumers for temporary external use to stop bleeding in minor wounds.

Quantifiable outcome

• 70% of severe bleeding cases stopped within 60 seconds of ChitoGauze treatment in Netherlands EMS study of 66 cases
• +3 more outcomes

Named customers7 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Six partnerships are on record, tiered core and minor.

• Medline IndustriescoreChannel Partner/ Reseller/ Distributor · 2 February 2021Exclusive 5-year distribution agreement for Tricol Biomedical family of hemostatic products. Initial term with annual increases in minimum purchases. Medline operates in 90+ countries with focus on North American hospital market. Jared Rosinski stated HemCon and OneStop brands support Medline's goal of cutting-edge products for better clinical outcomes.
• Safeguard MedicalcoreOEM/ Whitelabel/ Licensing Partner · 1 January 2020Private label/co-branding agreement allowing Safeguard to co-brand ChitoGauze XR PRO for worldwide sale and distribution. Keith Real, CTO, stated Tricol provided highest level of regulatory and supplier-related experience with on-time delivery of high-quality products.
• Tactical Medical Solutions (TacMed)coreStrategic or Co-development PartnerCo-development partnership for OLAES/HemCon Bandage. The OLAES dressing includes 12 feet of HemCon ChitoGauze and was designed with input from combat medics. Alan Hester, COO of TacMed, stated the partnership brought the best knowledge and experience.
• NorthStar Sales AllianceminorChannel Partner/ Reseller/ DistributorSales and marketing agency agreement for alternate site markets in U.S. Activates reach via strong GPO platform and engaged field team. John Linderman, CEO, noted products have been successfully used in professional healthcare market for over 20 years.
• Salvin Dental SpecialtiescoreChannel Partner/ Reseller/ DistributorExclusive U.S. distribution agreement for HemCon Dental Dressing PRO product line. Part of expanded GPO agreements including Premier and Vizient for hospital procedural care products.
• National Institutes of Health (NIH)minorOthers$853,585 Phase IIB STTR grant from National Institute of Diabetes and Digestive and Kidney Diseases for development of hemostatic device for prostate procedures. Grant number R42DK078400.

Scale indicators5 records

Recent moves6 records

Expansion highlights7 records

Emerging players

• Arch Therapeutics: Arch's AC5 self-assembling peptide hemostatic technology targets the same surgical and trauma hemostasis use cases as Tricol, though at a much earlier commercial stage.
• Marine Polymer Technologies: Developer of poly-N-acetyl glucosamine (p-GlcNAc) hemostatic products derived from marine sources, comparable as a biomaterial-based hemostasis platform with overlapping clinical use cases.

Broad incumbents

• BD (Becton Dickinson): BD offers a broad surgical and hemostasis portfolio through its Biosciences and Medical segments that overlaps with Tricol's procedural-care and wound-care applications in hospital channels.
• CSL Behring: CSL Behring's plasma-derived fibrin sealants and hemostasis biologics compete in the higher-acuity procedural and surgical hemostasis segment where Tricol's chitosan and oxidized cellulose products also play.
• Johnson & Johnson (Ethicon): Ethicon's Surgicel oxidized cellulose hemostatic family directly competes with Tricol's m.doc technology platform in operating-room surgical hemostasis, with substantially broader global distribution.
• Baxter International: Baxter's Floseal and Hemopatch hemostatic agents compete in the surgical and procedural-care hemostasis market, leveraging a far larger hospital sales force and broader product portfolio.

Direct peers

• Z-Medica (now part of Stryker): Z-Medica's QuikClot combat gauze is the closest direct competitor to ChitoGauze XR PRO, both being CoTCCC-approved hemostatic dressings for pre-hospital and battlefield hemorrhage control using a different (kaolin-based) mechanism.
• MedTrade Products: Celox chitosan-based hemostatic gauze from MedTrade Products is a direct material and clinical competitor to Tricol's Chito+ chitosan products, serving military, EMS, and civilian trauma markets.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/TricolBiomed
• YouTubeyoutube.com/channel/UCJv2iM9neGPiWomtdQu_aww
• Facebookfacebook.com/TricolBioMedicalInc
• LinkedInlinkedin.com/company/tricol-biomedical-inc.

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Tricol Biomedical Inc